Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    NXP900

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvectis Pharma Starts Phase 1B Study Of NXP900 With Osimertinib
    Nuvectis Pharma Starts Phase 1B Study Of NXP900 With Osimertinib

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206848/0/en/Nuvectis-Pharma-Announces-the-Initiation-of-the-Phase-1b-Study-of-NXP900-in-Combination-with-Osimertinib-in-Patients-with-NSCLC.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Nuvectis Hosts KOL on NXP900 Phase 1b Trial in Advanced Tumors
    Nuvectis Hosts KOL on NXP900 Phase 1b Trial in Advanced Tumors

    25 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3194268/0/en/Nuvectis-Pharma-to-Host-a-Virtual-Key-Opinion-Leader-Meeting-to-Discuss-the-NXP900-Phase-1b-Program-in-Advanced-Solid-Tumors-Including-the-Combination-with-Osimertinib-in-NSCLC.html

    GLOBENEWSWIRE
    25 Nov 2025
    Share Share
    Nuvectis Pharma Provides Poster Presentation Highlight for NXP900
    Nuvectis Pharma Provides Poster Presentation Highlight for NXP900

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174533/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Nuvectis Pharma To Present NXP900 At 2025 Cancer Therapeutics
    Nuvectis Pharma To Present NXP900 At 2025 Cancer Therapeutics

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167841/0/en/Nuvectis-Pharma-Announces-Upcoming-Presentations-for-NXP900-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.